Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.40% | 64.83% | 40.54% | 53.40% | 27.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.40% | 64.83% | 40.54% | 53.40% | 27.28% |
| Cost of Revenue | 215.81% | 187.17% | 129.26% | 123.84% | -17.39% |
| Gross Profit | 27.84% | 31.84% | 11.09% | 25.55% | 43.54% |
| SG&A Expenses | 17.54% | 34.74% | 50.38% | 63.57% | 48.99% |
| Depreciation & Amortization | -0.76% | -0.51% | 0.04% | -0.81% | -2.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.28% | 65.41% | 60.86% | 65.50% | 18.62% |
| Operating Income | 105.03% | 60.47% | -279.21% | -1,090.97% | 134.41% |
| Income Before Tax | 6,212.95% | 7.08% | -259.40% | -232.52% | -96.04% |
| Income Tax Expenses | 426.82% | 6.10% | -179.43% | -212.92% | -33.44% |
| Earnings from Continuing Operations | 3,186.63% | 7.38% | -280.02% | -237.65% | -107.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3,186.63% | 7.38% | -280.02% | -237.65% | -107.73% |
| EBIT | 105.03% | 60.47% | -279.21% | -1,090.97% | 134.41% |
| EBITDA | 38.99% | 17.81% | -55.10% | -47.78% | 25.72% |
| EPS Basic | 12,799.80% | -9.12% | -264.26% | -230.86% | -101.63% |
| Normalized Basic EPS | 438.58% | -371.44% | -809.82% | -2,875.49% | -332.46% |
| EPS Diluted | 3,710.73% | -17.72% | -273.26% | -233.88% | -105.55% |
| Normalized Diluted EPS | 412.51% | -424.68% | -818.03% | -2,933.86% | -345.16% |
| Average Basic Shares Outstanding | 6.38% | 7.57% | 7.51% | 6.81% | 5.74% |
| Average Diluted Shares Outstanding | 9.98% | 8.96% | 7.45% | 5.22% | 3.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |